Stéphane Bancel, CEO, reported third quarter revenue of $1 billion, driven by sales of fully approved vaccines including Spikevax, mNEXSPIKE, and mRESVIA, and announced a net loss of $200 million for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results